Chemoprevention of Hormone Receptor-Negative Breast Cancer: New Approaches Needed (original) (raw)
Anzano MA, Byers SW et al (1994) Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 54(17):4614–4617 PubMedCAS Google Scholar
Ariga R, Zarif A et al (2005) Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 11(4):278–280 ArticlePubMedCAS Google Scholar
Bonovas S, Filioussi K et al (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23(34):8606–8612 ArticlePubMed Google Scholar
Bryant HE, Schultz N et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913–917 ArticlePubMedCAS Google Scholar
Campbell MJ, Esserman LJ et al (2006) Breast cancer growth prevention by statins. Cancer Res 66(17):8707–8714 ArticlePubMedCAS Google Scholar
Cazzaniga M, Bonanni B et al (2009) Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 18(3):701–705 ArticlePubMedCAS Google Scholar
Chan KC, Knox WF et al (2001) Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg 88(3):412–418 ArticlePubMedCAS Google Scholar
Chlebowski R, Cuzick J et al (2009) Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 18(Suppl 2):S1–11 ArticlePubMed Google Scholar
Clay CE, Namen AM et al (1999) Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 20(10):1905–1911 ArticlePubMedCAS Google Scholar
Cummings SR, Eckert S et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. Jama 281(23):2189–2197 ArticlePubMedCAS Google Scholar
Cummings SR, Ensrud K et al (2010) “Lasofoxifene in postmenopausal women with osteoporosis.” N Engl J Med362(8): 686-96. ArticlePubMedCAS Google Scholar
Cuzick J (2003). Aromatase inhibitors in prevention – data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163:96–103; discussion 264–266 Google Scholar
Cuzick J (2008) IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 8(9):1377–1385 ArticlePubMedCAS Google Scholar
Cuzick J, Forbes JF et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer–96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99(4):272–282 ArticlePubMedCAS Google Scholar
Cuzick J, Powles T et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354):296–300 ArticlePubMedCAS Google Scholar
Dannenberg AJ, Lippman SM et al (2005) Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23(2):254–266 ArticlePubMedCAS Google Scholar
Dearth RK, Delgado DA et al (2010) Parity-induced decrease in systemic growth hormone alters mammary gland signaling: A potential role in pregnancy protection from breast cancer. Cancer Preve Res (Phila Pa) 3(3):312–321 ArticleCAS Google Scholar
Dunn BK, Ryan A (2009) Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators. Ann N Y Acad Sci 1155:141–161 ArticlePubMedCAS Google Scholar
Fisher B, Costantino JP et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662 ArticlePubMedCAS Google Scholar
Fisher B, Costantino JP et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388 ArticlePubMedCAS Google Scholar
Fong PC, Boss DS et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2): 123–134 ArticlePubMedCAS Google Scholar
Forbes JF, Cuzick J et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45–53 ArticlePubMed Google Scholar
Garwood ER, Kumar AS et al (2010) “Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.” Breast Cancer Res Treat119(1): 137-44. ArticlePubMedCAS Google Scholar
Giardiello FM, Brensinger JD et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6):1447–1453 ArticlePubMedCAS Google Scholar
Goodwin PJ (2008) Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol 26(6):833–834 ArticlePubMed Google Scholar
Goodwin PJ, Ligibel JA et al (2009) Metformin in breast cancer: time for action. J Clin Oncol 27(20):3271–3273 ArticlePubMedCAS Google Scholar
Goss PE, Richardson H et al (2007) National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer 7(11):895–900 ArticlePubMedCAS Google Scholar
Harris RE, Alshafie GA et al (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60(8): 2101–2103 PubMedCAS Google Scholar
Hong WK, Lippman SM et al (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323(12):795–801 ArticlePubMedCAS Google Scholar
Honig SF (2001) Tamoxifen for the reduction in the incidence of breast cancer in women at high risk for breast cancer. Ann N Y Acad Sci 949:345–348 ArticlePubMedCAS Google Scholar
Howe LR, Subbaramaiah K et al (2002) Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62(19):5405–5407 PubMedCAS Google Scholar
Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341–354 ArticlePubMedCAS Google Scholar
Ip MM, Masso-Welch PA et al (1999) Conjugated linoleic acid inhibits proliferation and induces apoptosis of normal rat mammary epithelial cells in primary culture. Exp Cell Res 250(1):22–34 ArticlePubMedCAS Google Scholar
Josefsson ML, Leinster SJ (2010) “Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in postmenopausal women: Meta-analyese of monotherapy, sequenced therapy and extended therapy.” Breast. Google Scholar
Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84(9):1188–1192 ArticlePubMedCAS Google Scholar
Kleinberg DL, Wood TL et al (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30(1):51–74 ArticlePubMedCAS Google Scholar
Kong G, Kim HT et al (2005) The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 65(8):3462–3469 PubMedCAS Google Scholar
Kumar AP, Quake AL et al (2009) Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. Cancer Res 69(22):8636–8644 ArticlePubMedCAS Google Scholar
Kumar AS, Benz CC et al (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 17(5):1028–1033 ArticlePubMedCAS Google Scholar
Kumar AS, Campbell M et al (2006) A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol 24(13):2127; author reply 2127–2128 Google Scholar
Larsson SC, Mantzoros CS et al (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121(4):856–862 ArticlePubMedCAS Google Scholar
Lee HY, Dawson MI et al (1996) Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells. Cell Growth Differ 7(8):997–1004 PubMedCAS Google Scholar
Lerner LJ, Holthaus FJ Jr et al (1958) A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology 63(3):295–318 ArticlePubMedCAS Google Scholar
Li Y, Zhang Y et al (2007) The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res 13(20):6224–6231 ArticlePubMedCAS Google Scholar
Liby K, Rendi M et al (2006) The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res 12(19):5902–5909 ArticlePubMedCAS Google Scholar
Liby K, Risingsong R et al (2008) Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. Clin Cancer Res 14(14): 4556–4563 ArticlePubMedCAS Google Scholar
Litzenburger BC, Kim HJ et al (2009) BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res 15(1):226–237 ArticlePubMedCAS Google Scholar
Lu C, Speers C et al (2003) Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95(24):1825–1833 ArticlePubMedCAS Google Scholar
Maggiora M, Bologna M et al (2004) An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int J Cancer 112(6):909–919 ArticlePubMedCAS Google Scholar
Mason RP, Walter MF et al (2004) Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 109(21 Suppl 1):II34–41 Google Scholar
Medina D, Kittrell F et al (2009) Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila Pa) 2(2):168–174 ArticleCAS Google Scholar
Mehta RG, Williamson E et al (2000) A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92(5):418–423 ArticlePubMedCAS Google Scholar
Moon RC, Thompson HJ et al (1979) N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 39(4):1339–1346 PubMedCAS Google Scholar
Moulder SL, Yakes FM et al (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61(24):8887–8895 PubMedCAS Google Scholar
Mueck AO, Seeger H et al (2003) Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 10(4):332–336 ArticlePubMed Google Scholar
Mueller E, Sarraf P et al (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1(3):465–470 ArticlePubMedCAS Google Scholar
Papa V, Belfiore A (1996) Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest 19(5):324–333 PubMedCAS Google Scholar
Powles TJ, Ashley S et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99(4):283–290 ArticlePubMedCAS Google Scholar
Rendi MH, Suh N et al (2004) The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Res 64(10):3566–3571 ArticlePubMedCAS Google Scholar
Rigas B, Kashfi K (2005) Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther 314(1):1–8 ArticlePubMedCAS Google Scholar
Salh B, Marotta A et al (1999) Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 19(1B):731–740 Google Scholar
Savage DG, Antman KH (2002) Imatinib mesylate–a new oral targeted therapy. N Engl J Med 346(9):683–693 ArticlePubMedCAS Google Scholar
Sawyers CL, Hochhaus A et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99(10):3530–3539 ArticlePubMedCAS Google Scholar
Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2):138–146 ArticlePubMedCAS Google Scholar
Seewaldt VL, Kim JH et al (1997) All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ 8(6):631–641 PubMedCAS Google Scholar
Shaw RJ, Lamia KA et al (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5754):1642–1646 ArticlePubMedCAS Google Scholar
Strecker TE, Shen Q et al (2009) Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 101(2):107–113 ArticlePubMedCAS Google Scholar
Suh N, Wang Y et al (1999) A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 59(22):5671–5673 PubMedCAS Google Scholar
Szanto A, Narkar V et al (2004) Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ 11(Suppl 2):S126–143 ArticlePubMedCAS Google Scholar
Tutt A et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. J Clin Oncol (Suppl) 27(18s): Abstr. CRA501 Google Scholar
Uray IP, Shen Q et al (2009) Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 284(1):345–353 ArticlePubMedCAS Google Scholar
Vazquez-Martin A, Oliveras-Ferraros C et al (2009) The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 20(3):592–595 ArticlePubMedCAS Google Scholar
Veronesi U, Maisonneuve P et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99(9):727–737 ArticlePubMedCAS Google Scholar
Vogel VG, Costantino JP et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741 ArticlePubMedCAS Google Scholar
Wendel M, Heller AR (2009) Anticancer actions of omega-3 fatty acids – current state and future perspectives. Anticancer Agents Med Chem 9(4):457–470 ArticlePubMedCAS Google Scholar
Woditschka S, Haag JD et al (2006) Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas. Cancer Res 66(13):6884–6891 ArticlePubMedCAS Google Scholar
Wolbach SB, Howe PR (1925) Tissue changes following deprivation of fat-soluble a vitamin. J Exp Med 42(6):753–777 ArticlePubMedCAS Google Scholar
Wu K, DuPre E et al (2006) Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res Treat 96(2):147–157 ArticlePubMedCAS Google Scholar
Wu K, Kim HT et al (2002a) Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11(5):467–474 PubMedCAS Google Scholar
Wu K, Kim HT et al (2000) 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res 6(9):3696–3704 PubMedCAS Google Scholar
Wu K, Zhang Y et al (2002b) The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62(22):6376–6380 PubMedCAS Google Scholar
Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 86(3):s823–835 PubMed Google Scholar
Yang L, Ostrowski J et al (2001) The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. Oncogene 20(55):8025–8035 ArticlePubMedCAS Google Scholar
Yin F, Bruemmer D et al (2004) Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene 23(26):4614–4623 ArticlePubMedCAS Google Scholar
Yin F, Wakino S et al (2001) Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 286(5):916–922 ArticlePubMedCAS Google Scholar
Zakikhani M, Dowling R et al (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66(21):10269–10273 ArticlePubMedCAS Google Scholar